Merck Animal Health Launches Nobivac® Intra-Trac® Oral BbPi for Dual Prevention of Two Major Canine Respiratory Pathogens
First-of-its-kind oral vaccine provides 2-in-1 coverage against canine parainfluenza virus and Bordetella bronchiseptica
New Immuno-Mist-RTM applicator delivers broad protection and enhances ease of use and pet comfort
MADISON, N.J., September 12, 2022 – Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co, Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. launch of Nobivac® Intra-Trac® Oral BbPi, the first and only oral Bordetella bronchiseptica-canine parainfluenza virus vaccine that offers mucosal protection with easy oral administration. The Nobivac® Intra-Trac® Oral BbPi proprietary oral formulation and revolutionary Immuno-Mist-R™ delivery system make oral protection against canine parainfluenza possible, at last. The product’s unique Immuno-Mist-RTM Applicator provides extensive spray coverage that more efficiently delivers broad protection for dogs while significantly enhancing ease of use for veterinarians and veterinary technicians, and comfort for canine patients.
Nobivac Intra-Trac Oral BbPi is a groundbreaking addition to Merck Animal Health’s Intra-Trac respiratory portfolio. Nobivac Intra-Trac Oral BbPi has been shown to be effective for vaccination of healthy dogs seven weeks of age or older against canine parainfluenza virus and Bordetella bronchiseptica. The product is thimerosal-free and contains no preservatives. With this first-of-a-kind product, veterinarians and support staff can now offer clients dual protection against two major respiratory pathogens while providing a better vaccination experience for dogs. In addition, the breakthrough technology of the Immuno-Mist-R applicator was instrumental in achieving an effective oral parainfluenza vaccine.
“For dogs in social environments, including parks, boarding kennels and daycares, co-infection of the respiratory tract with two or more pathogens is often observed,” said Madeleine Stahl, DVM, associate director medical affairs, Merck Animal Health. “Given the role that Bordetella and parainfluenza play in the canine infectious respiratory disease complex, preventing the spread of both is critical to protect the respiratory health of social dogs and lessen the possibility of future outbreaks – and Nobivac Intra-Trac Oral BbPi does just that.”
Canine parainfluenza spreads rapidly among susceptible dogs that interact with one another frequently or are housed in close confinement, and is among the most common causes of highly contagious acute-onset cough in dogs throughout the world.1 Because the virus is excreted from the respiratory tract of infected dogs for up to 10 days after infection and is transmitted through the air, it can quickly become difficult to control.1,2 Nobivac Intra-Trac Oral BbPi was designed to deliver mucosal immunity with a simple oral application that is more convenient for the veterinarian and less stressful for the pet and pet owner.
“As a company that is committed to providing technology and veterinary services that advance animal healthcare, the introduction of Nobivac Intra-Trac Oral BbPi and the first-of-its-kind Immuno-Mist-R applicator perfectly complement the portfolio of vaccines we offer to veterinarians,” said Laura Greene, DVM, DACVIM sr. professional services veterinarian – internal medicine at Merck Animal Health. “We are confident that both veterinary professionals and the dogs in their care will benefit from the convenience and comfort that Nobivac Intra-Trac Oral BbPi offers, against two very important respiratory pathogens in dogs.”
The vaccine will be available for veterinary professionals to administer in trays of 25 x 1 dose desiccated vaccine vials and 25 x 1 dose (1 mL) sterile diluent vials. Luer lock syringes demarcated with green plungers and labeled “For use with NOBIVAC® INTRA-TRAC® ORAL BbPi,” as well as Immuno-Mist-R applicator tips will be provided with the purchase of each vaccine tray. Using the Luer lock syringes and Immuno-Mist-R tips, Nobivac Intra-Trac Oral BbPi is administered by gently misting the vaccine orally towards the back of the mouth.
NOBIVAC Intra-Trac Oral BbPi is expected to become available for veterinary clinics to purchase in the U.S. in fall 2022. To learn more about Merck Animal Health’s history of innovation with its NOBIVAC® portfolio, visit www.Nobivac.com.
About Merck Animal Health
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
